New hypertension pill VB19055 enters first human safety trial
NCT ID NCT07254481
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a new tablet called VB19055 in 86 healthy Chinese adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo. The goal is to gather initial safety data before testing in people with high blood pressure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VB19055
What this could lead to
If successful, this could lead to a new medication option for controlling high blood pressure.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not patients. It primarily checks safety, not effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hangzhou First People's Hospital
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
NOT_YET_RECRUITINGShanghai, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••